Is PCOS Officially an Autoimmune Disease?

PCOS is not classified as an autoimmune disease by any major medical organization or diagnostic guideline. It remains categorized as an endocrine (hormonal) disorder. But the question keeps coming up for good reason: women with PCOS show patterns of immune dysfunction, chronic inflammation, and autoantibody production that overlap uncomfortably with what researchers see in recognized autoimmune conditions. The science behind that overlap is more interesting than a simple yes or no.

Why PCOS Gets Confused With Autoimmune Disease

The confusion stems from several real findings that, taken individually, could each point toward autoimmunity. Women with PCOS tend to have elevated levels of inflammatory markers like C-reactive protein, tumor necrosis factor alpha (TNF-α), and several interleukins, even after accounting for differences in body weight.¹ Some women with PCOS produce autoantibodies, the immune proteins that mistakenly target the body’s own tissues and are a hallmark of autoimmune disease. A 2025 review noted that while various autoantibodies targeting the hormonal axis have been found in PCOS, the evidence remains difficult to interpret because women with PCOS seem broadly predisposed to higher autoantibody levels in general.² And PCOS shows up alongside established autoimmune diseases at rates higher than chance would predict.

That said, having some autoimmune-like features is not the same as being an autoimmune disease. Classic autoimmune diseases share a defining trait: the immune system specifically and directly attacks a part of the body, causing tissue damage. In type 1 diabetes, immune cells destroy insulin-producing cells in the pancreas. In Hashimoto’s thyroiditis, they attack the thyroid gland. No equivalent targeted self-attack has been definitively identified in PCOS. The immune abnormalities appear to be secondary to, or tangled up with, hormonal and metabolic dysfunction rather than being the primary driver.

The Chronic Inflammation Problem

One of the strongest immune-related findings in PCOS is persistent, low-grade inflammation. This is not the acute inflammation you get from an infection or injury. It is a slow-burn state where inflammatory signaling molecules stay slightly elevated all the time. Studies comparing women with PCOS to weight-matched controls have found higher white blood cell counts, higher CRP, and higher levels of inflammatory cytokines like IL-6, IL-18, and TNF-α.¹ The weight-matching part matters: it is well known that carrying extra body fat raises inflammatory markers on its own. But even when researchers control for that, women with PCOS still show higher inflammation.

Research on what drives this inflammation has pointed in two directions. One is body weight and insulin resistance: higher BMI and higher insulin levels both predict higher CRP in PCOS.³ The other is androgen levels themselves. In the same study, white blood cell counts were independently associated with testosterone concentration, suggesting that the excess androgens characteristic of PCOS may stoke inflammation through a pathway that does not depend on being overweight.³ This dual-channel inflammation, partly metabolic and partly hormonal, is one of the features that makes PCOS look autoimmune-adjacent even though no specific autoimmune mechanism has been proven.

How Excess Androgens Reshape the Immune System

Androgens are not just bystanders in the immune story. Excess androgens appear to actively distort how the immune system operates. The general picture is that hyperandrogenism revs up some immune cells and suppresses others, creating an imbalance that feeds chronic inflammation.⁴ That same dysregulated immune response has been described as showing “autoimmunity characteristics,” though researchers are careful to say those characteristics need more investigation rather than a definitive label.⁴

A 2024 mouse study added detail to this picture. When mice were exposed to high levels of dihydrotestosterone (a potent androgen) to mimic PCOS, their immune cell populations shifted in tissue-specific ways. The uterus showed higher numbers of natural killer cells and elevated levels of inflammatory signaling molecules like IFN-γ and TNF-α. Eosinophils, an immune cell type involved in controlling inflammation, dropped sharply in both the uterus and abdominal fat. Macrophages, the immune system’s cleanup and surveillance cells, were altered in the ovaries, uterus, and fat tissue. When the researchers blocked androgen receptors, most of these changes reversed, confirming that the immune disruption was driven directly through androgen signaling.⁵

This creates a vicious cycle that researchers have been tracking. Inflammation itself can stimulate ovarian cells to produce more androgens, and those androgens in turn feed more inflammation. In vitro work has shown that inflammatory stimuli can directly ramp up the ovarian enzyme responsible for androgen production.⁶ It is a feedback loop without a clean starting point, which is part of why it has been so hard to determine whether the immune dysfunction in PCOS is a cause or a consequence.

Immune Cell Imbalances in Women With PCOS

Beyond broad inflammatory markers, researchers have looked directly at which immune cell populations are different in PCOS. The findings are consistent enough to be noteworthy but messy enough to resist a single tidy narrative.

T cells, which orchestrate much of the immune response, show several abnormalities. A study of infertile women with PCOS found significantly reduced proportions of certain T cell subsets in the fluid surrounding their developing eggs, compared to infertile women without PCOS.⁷ At a broader level, PCOS appears to tip the balance of T cell subtypes. In a study comparing women with PCOS to healthy fertile women, the ratio of pro-inflammatory T cell types (Th1 and Th17 cells) to anti-inflammatory types (Th2 and regulatory T cells) was skewed toward inflammation. Regulatory T cells, which normally keep immune responses in check and prevent autoimmunity, were significantly lower in the PCOS group.⁸

That reduction in regulatory T cells is particularly suggestive. In established autoimmune diseases like type 1 diabetes and lupus, deficits in regulatory T cells are a known part of the pathology. Finding a similar pattern in PCOS adds to the circumstantial case for autoimmune involvement. But it is circumstantial: reduced regulatory T cell function can also result from metabolic stress, obesity, or chronic hormonal disruption without implying that the immune system is attacking self-tissue. The immune system in PCOS is demonstrably abnormal. Whether it is abnormal in the specific way that defines autoimmune disease remains unresolved.⁹

PCOS Travels With Autoimmune Diseases

If PCOS is not autoimmune, it keeps suspiciously close company with conditions that are. The most studied overlap is with Hashimoto’s thyroiditis, the most common autoimmune thyroid condition. A systematic review and meta-analysis pooling data from thousands of patients found that roughly a quarter of women with PCOS also had Hashimoto’s, compared to about 14% of controls. Women with PCOS were more than twice as likely to have the condition.¹⁰ A separate meta-analysis looking more broadly at autoimmune thyroid disease (including Graves’ disease as well as Hashimoto’s) found an even stronger association, with PCOS women about three times as likely to have autoimmune thyroid disease as healthy controls.¹¹

Links to lupus have also drawn interest. One review noted that women with PCOS express many of the same antibodies found in lupus patients, fueling speculation about a shared autoimmune thread.¹² And a bioinformatics analysis comparing gene expression in PCOS, rheumatoid arthritis, and osteoarthritis found hundreds of overlapping biological pathways, including pathways involved in immune regulation, mitochondrial dysfunction, and oxidative stress.¹³ The overlap does not prove a shared autoimmune cause. But it suggests that whatever is going wrong in PCOS involves many of the same molecular machinery that autoimmune diseases rely on.

The Gut Microbiome as a Possible Bridge

An emerging line of research points to the gut as a potential link between PCOS and immune dysfunction. Women with PCOS tend to have an altered gut microbiome, with certain bacterial populations overrepresented. Some of these bacteria, like Escherichia and Shigella, have been associated with gut dysbiosis that leads to systemic inflammation and hormonal disruption.¹⁴

The proposed mechanism goes like this: when the gut barrier becomes leaky due to microbial imbalance, bacterial products slip into the bloodstream and trigger an immune response, including the release of pro-inflammatory cytokines and antibodies.¹⁵ This systemic immune activation could feed into the same inflammatory cycle that drives androgen excess and insulin resistance. Gut permeability and microbiome changes are also implicated in several recognized autoimmune diseases, including type 1 diabetes and inflammatory bowel disease, so the presence of a similar pathway in PCOS further blurs the boundary between “endocrine disorder” and “immune-mediated condition.”

The Stress Response Adds Another Layer

The immune story in PCOS extends to how the body responds to stress. A study comparing PCOS patients to weight-matched controls found that women with PCOS had exaggerated cortisol and ACTH responses to a psychosocial stressor, but a blunted IL-6 response. In healthy people, IL-6 typically rises after stress as part of the body’s coordinated immune-endocrine reaction. In the PCOS group, that rise was dampened.¹⁶ This is a subtle finding, but it suggests that the immune-endocrine wiring in PCOS is altered in ways that go beyond simple “more inflammation.” The system is not just louder across the board; it is miscalibrated, responding too much to some signals and too little to others.

What This Means for Treatment

If PCOS has a meaningful autoimmune or immune-mediated component, then treatments that address inflammation should help, and there is growing evidence that they do. Metformin, the insulin-sensitizing drug that is already a standard PCOS treatment, has demonstrated anti-inflammatory effects beyond its metabolic role. In a randomized clinical trial, metformin reduced levels of IL-8 (an inflammatory cytokine) and improved insulin resistance, while a combination of metformin and pioglitazone also significantly lowered IL-6.¹⁷ Whether these anti-inflammatory effects contribute independently to symptom improvement, or whether they are simply a side benefit of metabolic improvement, is still being teased apart.

More experimental approaches are being explored specifically because of the immune angle. Researchers have tested engineered tiny vesicles derived from stem cells that act as both targeted delivery vehicles and immune modulators. In a mouse model, these vesicles reduced ovarian inflammation, normalized follicular development, and improved glucose and insulin balance.¹⁸ This is still early-stage animal research, far from clinical use. But it signals that the field is taking the immune dimension of PCOS seriously enough to design therapies around it.

Why Classification Matters More Than It Sounds

Whether PCOS gets reclassified as autoimmune, immune-mediated, or stays firmly in the endocrine category is not just a labeling exercise. Disease classification shapes research funding, insurance coverage, and the types of specialists involved in care. If PCOS were recognized as having a substantial immune component, it could justify coverage for immunological testing, open the door to clinical trials of anti-inflammatory therapies, and encourage referrals to immunologists alongside endocrinologists and gynecologists. Right now, the dominant treatment framework centers on managing individual symptoms: birth control pills for irregular cycles and acne, metformin for insulin resistance, spironolactone for excess hair growth. A classification that acknowledged immune dysfunction could push the field toward treatments that address the underlying biology more directly.

The resistance to reclassification is not stubbornness. It is the reasonable scientific position that the evidence, while intriguing, does not yet meet the bar. No specific autoantigen (a self-protein the immune system attacks) has been firmly identified in PCOS. The immune abnormalities documented so far could all be downstream consequences of metabolic and hormonal disruption rather than independent drivers. And the heterogeneity of PCOS, which can present very differently from one woman to the next, makes it possible that immune involvement is central in some patients and peripheral in others.

An Evolutionary Angle on the Immune Question

One less obvious way to think about PCOS and immunity comes from evolutionary biology. Some researchers have proposed that the cluster of traits we now call PCOS may have been adaptive in ancestral environments where food was scarce and unpredictable. Under this “environmental mismatch” hypothesis, features like insulin resistance and androgen excess could have helped with energy storage and survival during famine. When those same traits operate in a modern environment of caloric abundance, they become pathological.¹⁹ Among the putative ancestral benefits that have been proposed are not just metabolic advantages but also immune system dynamics, suggesting that the immune features of PCOS may have once served a protective role, perhaps providing a more aggressive inflammatory response to infection in environments where that was a major threat.²⁰

If that is the case, the immune dysfunction in PCOS may not be a malfunction at all in the classical sense. It may be a calibration that worked well under very different conditions and now overshoots in a world of high caloric availability and low infectious disease pressure. This does not resolve the autoimmune question, but it reframes it: instead of asking whether the immune system is attacking the body, the relevant question might be whether it is tuned to an environment that no longer exists.

Pregnancy Risk and Immune Factors

One practical area where immune dysfunction in PCOS has real consequences is pregnancy. Women with PCOS face a higher risk of pregnancy loss, and while hormonal and metabolic factors like obesity and insulin resistance are part of the explanation, immune abnormalities likely play a role as well.²¹ Successful pregnancy requires a carefully coordinated shift in the mother’s immune system toward tolerance of the developing embryo. The pro-inflammatory skew and reduced regulatory T cell function seen in PCOS could interfere with that process, making it harder for the immune system to accept the pregnancy. This is speculative but fits with the broader pattern: the immune system in PCOS behaves as though it is not just inflamed but poorly regulated, reacting in ways that are slightly wrong for the situation at hand.

For women with PCOS who are trying to conceive, this suggests that managing inflammation, not just inducing ovulation, may be an important part of fertility care. Lifestyle interventions that reduce insulin resistance, such as regular physical activity and dietary changes, also tend to lower inflammatory markers, which could have a double benefit. Whether targeted anti-inflammatory therapies would improve pregnancy outcomes in PCOS is an open question that clinical trials have not yet answered definitively.